Matthew Kay, MD
Ophthalmology · Boca Raton, FLNPI 1568462489
Payments from drug & device makers
Across 409 payments — averaging $619.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$245K
- AstraZeneca$3K
- AbbVie$1K
- NEW World Medical,inc.$968
- Alcon$548
- Johnson & Johnson Surgical Vision, Inc.$373
- plus $3K from 18 others
What the payments were for
- Consulting fees$6,1102%
- Speaking & faculty fees$196,71578%
- Travel & lodging$33,74313%
- Food & beverage$16,9517%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 353 | $245,063 |
| AstraZeneca | 8 | $2,918 |
| AbbVie(2 entities) | 13 | $1,040 |
| NEW World Medical,inc. | 2 | $968 |
| Alcon | 5 | $548 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $373 |
| Bausch & Lomb Americas Inc. | 3 | $321 |
| Dompe US, Inc. | 2 | $272 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $272 |
| Omeros Corporation | 2 | $250 |
| Beaver-visitec International, Inc. | 1 | $198 |
| Glaukos Corporation | 1 | $170 |
| Mallinckrodt Hospital Products Inc. | 1 | $136 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $124 |
| Idorsia Pharmaceuticals US Inc | 1 | $119 |
| Kala Pharmaceuticals, Inc. | 1 | $118 |
| Eyevance Pharmaceuticals LLC | 1 | $111 |
| ANI Pharmaceuticals, Inc. | 1 | $103 |
| Coopervision Inc. | 1 | $101 |
| Argenx US, Inc. | 1 | $75 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$225,148
- SOLIRIS$2,482
- Kahook Dual Blade$968
- Streamline Surgical System$968
- Ahmed Glaucoma Valve$968
- STELLARIS$302
- Clareon$274
- Oxervate$272
- OMIDRIA$250
- DURYSTA$248
- Tecnis IOL$244
- enVista MX60 IOL$176
- AMVISC PLUS$176
- iStent Trabecular Micro-Bypass Stent System$170
- iStent inject Trabecular Micro-Bypass Stent System$170
- AMO PHACO NEEDLE$141
- OZURDEX$138
- ACTHAR$136
- ULTOMIRIS$128
- ENVISTA$127
How this compares
$253,565 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 26 | $4,837 |
| Prednisone | 37 | $424 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boca Raton
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.